• Je něco špatně v tomto záznamu ?

Cyclin D1 mRNA as a molecular marker for minimal residual disease monitoring in patients with mantle cell lymphoma

M. Lokvenc, M. Kalinova, K. Forsterova, P. Klener, M. Trneny, E. Fronkova, R. Kodet,

. 2018 ; 97 (3) : 467-474. [pub] 20171222

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18010231

Grantová podpora
NV17-28980A MZ0 CEP - Centrální evidence projektů

Chromosomal translocation t(11;14)(q13;q32) is a characteristic molecular marker of mantle cell lymphoma (MCL) and leads to the fusion of the immunoglobulin heavy chain enhancer-promoter with the cyclin D1 gene. Both aberrant cyclin D1 expression and underlying chromosomal aberration may be used as molecular targets for monitoring minimal residual disease (MRD). The present study aims to assess the usefulness of quantitative cyclin D1 gene expression compared to the standardised but more technologically demanding DNA-based method for immunoglobulin heavy chain (IGH) or t(11;14) clone-specific gene rearrangement quantification in a cohort of bone marrow (BM) and peripheral blood (PB) samples from patients with MCL. We simultaneously evaluated DNA-MRD and cyclin D1 expression levels in 234 samples from 57 patients. We observed that both in DNA-MRD positive and negative BM/PB pairs from the same time points the expression levels of cyclin D1 are lower in PB than in BM (median 19×, BM/PB range 0.41-352). The correlation of cyclin D1 transcript levels with DNA-MRD or with flow cytometry was good only in samples with a very high infiltration. In DNA-MRD-negative BM samples, we observed a significant heterogeneity of cyclin D1 expression (in the range of more than three orders of magnitude). This is in contrast to previous reports demonstrating the usefulness of cyclin D1 for MRD monitoring that did not use DNA-based method as a reference. In PB, the specificity of cyclin D1 expression was better due to a lower physiological background. In conclusion, we show that cyclin D1 is unsuitable for MRD monitoring in BM.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18010231
003      
CZ-PrNML
005      
20180417111945.0
007      
ta
008      
180404s2018 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00277-017-3210-8 $2 doi
035    __
$a (PubMed)29273915
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Lokvenc, M $u Department of Pathology and Molecular Medicine, University Hospital Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
245    10
$a Cyclin D1 mRNA as a molecular marker for minimal residual disease monitoring in patients with mantle cell lymphoma / $c M. Lokvenc, M. Kalinova, K. Forsterova, P. Klener, M. Trneny, E. Fronkova, R. Kodet,
520    9_
$a Chromosomal translocation t(11;14)(q13;q32) is a characteristic molecular marker of mantle cell lymphoma (MCL) and leads to the fusion of the immunoglobulin heavy chain enhancer-promoter with the cyclin D1 gene. Both aberrant cyclin D1 expression and underlying chromosomal aberration may be used as molecular targets for monitoring minimal residual disease (MRD). The present study aims to assess the usefulness of quantitative cyclin D1 gene expression compared to the standardised but more technologically demanding DNA-based method for immunoglobulin heavy chain (IGH) or t(11;14) clone-specific gene rearrangement quantification in a cohort of bone marrow (BM) and peripheral blood (PB) samples from patients with MCL. We simultaneously evaluated DNA-MRD and cyclin D1 expression levels in 234 samples from 57 patients. We observed that both in DNA-MRD positive and negative BM/PB pairs from the same time points the expression levels of cyclin D1 are lower in PB than in BM (median 19×, BM/PB range 0.41-352). The correlation of cyclin D1 transcript levels with DNA-MRD or with flow cytometry was good only in samples with a very high infiltration. In DNA-MRD-negative BM samples, we observed a significant heterogeneity of cyclin D1 expression (in the range of more than three orders of magnitude). This is in contrast to previous reports demonstrating the usefulness of cyclin D1 for MRD monitoring that did not use DNA-based method as a reference. In PB, the specificity of cyclin D1 expression was better due to a lower physiological background. In conclusion, we show that cyclin D1 is unsuitable for MRD monitoring in BM.
650    _2
$a nádorové biomarkery $x analýza $x genetika $7 D014408
650    _2
$a kostní dřeň $x metabolismus $x patologie $7 D001853
650    _2
$a cyklin D1 $x genetika $x metabolismus $7 D019938
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a lymfom z plášťových buněk $x diagnóza $x genetika $x patologie $7 D020522
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a monitorování fyziologických funkcí $x metody $7 D008991
650    _2
$a reziduální nádor $7 D018365
650    _2
$a messenger RNA $x analýza $7 D012333
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kalinova, Marketa $u Department of Pathology and Molecular Medicine, University Hospital Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic. marketa.kalinova@lfmotol.cuni.cz.
700    1_
$a Forsterova, K $u First Department of Medicine - Department of Haematology, Charles University General Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Klener, P $u First Department of Medicine - Department of Haematology, Charles University General Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Trneny, M $u First Department of Medicine - Department of Haematology, Charles University General Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Fronkova, E $u CLIP - Childhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Kodet, R $u Department of Pathology and Molecular Medicine, University Hospital Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
773    0_
$w MED00000424 $t Annals of hematology $x 1432-0584 $g Roč. 97, č. 3 (2018), s. 467-474
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29273915 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20180417112043 $b ABA008
999    __
$a ok $b bmc $g 1287716 $s 1007043
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 97 $c 3 $d 467-474 $e 20171222 $i 1432-0584 $m Annals of hematology $n Ann Hematol $x MED00000424
GRA    __
$a NV17-28980A $p MZ0
LZP    __
$a Pubmed-20180404

Najít záznam

Citační ukazatele

Možnosti archivace